Beijing Atomic High-tech

Beijing Atomic High-tech is a leading Chinese radiopharmaceutical company specializing in the research, development, production, and distribution of radioactive drugs and diagnostic tracers. As a core subsidiary of China Isotope & Radiation Corporation (CIRC), the company operates an extensive network of regional radiopharmacies across China to ensure the timely delivery of short-lived isotopes. Its commercial portfolio includes essential products such as Iodine-131 for thyroid therapy and Fluorine-18 FDG for PET imaging, alongside various Technetium-99m generators. The company is aggressively expanding its R&D pipeline to include next-generation therapeutic radiopharmaceuticals, specifically targeting prostate cancer and neuroendocrine tumors with Lutetium-177 labeled compounds. Beijing Atomic High-tech plays a pivotal role in China's nuclear medicine infrastructure, supporting both routine clinical diagnostics and advanced oncological treatments.